Search

Displaying results 4881 - 4890 of 6830 in total
  1. Drug

    KB3305

    go.drugbank.com/drugs/DB06349
    Experimental

    KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.

  2. Drug

    OMS906

    go.drugbank.com/drugs/DB17722
    Investigational

    OMS906 is a humanized Igg4 monoclonal antibody against mannan-binding lectin-associated serine protease-3 (MASP-3) currently being developed by Omeros.

  3. Drug

    Seliforant

    go.drugbank.com/drugs/DB15220
    Investigational

    Seliforant is under investigation in clinical trial NCT01260753 (Proof of Activity Study of UR-63325 in Allergic Rhinitis Induced by Nasal Challenge).

  4. Drug

    Cephalothin Group

    go.drugbank.com/drugs/DB03450
    Experimental

    This compound belongs to the 1,3-thiazines. … This substance is known to target beta-lactamase Toho-1 and D-alanyl-D-alanine carboxypeptidase.

  5. Drug

    Calcium phosphate dihydrate

    go.drugbank.com/drugs/DB14481
    Approved

  6. Drug

    Inolimomab

    go.drugbank.com/drugs/DB15628
    Investigational

    Inolimomab is under investigation as an agent to treat steroid-resistant graft vs host disease. … It has thus far offered similar efficacy to other monoclonal antibody options, though it may carry a higher risk of infections.[A241385]

  7. Drug

    Bifonazole

    go.drugbank.com/drugs/DB04794
    Approved

    Bifonazole is an azole antifungal drug.

  8. Drug

    Enalaprilat

    go.drugbank.com/drugs/DB09477
    ApprovedInvestigational

    Enalaprilat was originally created to overcome the limitations of the first ACE inhibitor, captopril, which had numerous side effects and left a metallic taste in the mouth. … Removal of the problematic thiol group from captopril resulted in enalaprilat, which was then modified further with an ester to create the orally available pro-drug enalapril.

  9. Drug

    Methyprylon

    go.drugbank.com/drugs/DB01107
    ApprovedIllicitWithdrawn

    Methyprylon was withdrawn from the U.S. market in June 1965 and the Canadian market in September 1990 due to adverse events.

  10. Drug

    PRLX 93936

    go.drugbank.com/drugs/DB06098
    Investigational

    PRLX 93936 is selectively toxic to cancer cells.